KLK3 and prostate cancer: Following from this initial study,a randomized placebo-controlled Phase II trial of rosiglitazone (8 mg/day) wasconducted in prostate cancer patients with progressive disease evidenced by arise in serum levels of PSA following local treatment with radicalprostatectomy and/or radiation therapy [86].